Leidos Gets Patent for Peptide-Class of Checkpoint Inhibitors
Leidos’ life sciences unit has secured a U.S. patent for its new peptide-based PD-1 checkpoint inhibitors developed for more targeted delivery of treatments. The company said Thursday that the U.S. Patent and Trademark Office issued the patent for Leidos Health Life Sciences through the Patents 4 Patients program. The program provides a faster review process […] More